Balyasny Asset Management
CMPX icon

Balyasny Asset Management’s Compass Therapeutics CMPX Stock Holding History

Balyasny Asset Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-332,100
Closed -$631K – 2891
2025
Q1 		$631K Buy
+332,100
New +$883K ﹤0.01% 2190

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Balyasny Asset Management's CMPX Position: Q2 2026 in Review

Balyasny Asset Management sold out of Compass Therapeutics (CMPX) in Q2 2026, closing a stake of 1,119,090 shares — an estimated $5.92M sold.

Balyasny Asset Management first reported a position in CMPX in Q4 2022 and held it in 5 quarters. The position peaked at $9.89M in Q3 2025. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Balyasny Asset Management reported no remaining Compass Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 1,119,090 Compass Therapeutics shares in Q2 2026, an estimated $5.92M.
  • Balyasny Asset Management first reported a position in Compass Therapeutics in Q4 2022 and held it in 5 quarters.
  • Balyasny Asset Management's Compass Therapeutics position peaked at $9.89M in Q3 2025.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.